COMMENT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Pediatric Exposures to Electronic Cigarettes Reported to Texas Poison Centers.

BACKGROUND: Electronic cigarette use is increasing. There are concerns that pediatric exposures to these products may result in serious adverse affects.

OBJECTIVES: This study describes pediatric exposures to electronic cigarettes.

METHODS: Cases were electronic cigarette exposures among patients age 5 years or less reported to Texas poison centers during January 2010-June 2014. The distribution by selected variables was determined.

RESULTS: Of 203 exposures, two cases were reported in 2010, five in 2011, 20 in 2012, 70 in 2013, and 106 in January-June 2014. Fifty-one percent of the patients were male; 32% of the patients were aged 1 year, and 42% were 2 years of age. Ninety-six percent of the exposures occurred at the patient's own residence. The exposure routes were ingestion (93%), dermal (11%), ocular (3%), and inhalation (2%). Fifty-eight percent of the patients were managed on site. Of the patients seen at a health care facility, 69% were treated or evaluated and released. Eleven percent of the exposures were serious. The most commonly reported clinical effects were vomiting (24%), drowsiness/lethargy (2%), and cough/choke (2%). The most frequent treatments were dilution/irrigation/wash (65%) and food/snack (16%).

CONCLUSIONS: Electronic cigarette exposures involving young children reported to poison centers are increasing. Such exposures are likely to involve patients ages 2-3 years, occur at the child's own residence, and occur by ingestion. Further study is needed to determine which subgroups are at risk for serious outcomes and warrant evaluation at a health care facility.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app